Skip Navigation

Adalvo announces successful Pivotal BE program for Dapagliflozin

03 February 2023

We are pleased to announce that we have now completed our Pivotal BE program for Dapagliflozin 10mg film-coated tablets. This product has been developed in collaboration with one of our strategic partners.

Our product has been developed based on the reference brand Forxiga 10mg film-coated tablets, which is indicated in the treatment of type 2 diabetes, heart failure and chronic (long-term) kidney disease.

The brand sold approximately $5bn globally in 2021, having a significant growth potential with Global 3Y CAGR at +44%, according to IQVIA.

Based on our positive progress, we believe that we will be ready for launch on Day-1. This development further showcases our ability to bring differentiated products to our partners.

Adalvo is able to offer a number of dossiers within this domain, as depicted below.